John Challier

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy

Christina Claus, Claudia Ferrara, Wei Xu et al. · Science Translational Medicine · 2019 · 266 citations · Full text

Medicine, Immunology, Oncology +17

Adenosine and <scp>cAMP</scp> signalling skew human dendritic cell differentiation towards a tolerogenic phenotype with defective CD8⁺ T‐cell priming capacity

John Challier, Denis Bruniquel, Andrew K. Sewell et al. · Immunology · 2012 · 77 citations · Full text

Life Sciences, Immunology, Oncology +17

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody

Christian Augsberger, Gerulf Hänel, Wei Xu et al. · Blood · 2021 · 68 citations · Full text

Life Sciences, Immunology, Oncology +14

Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies

Gabrielle Leclercq-Cohen, Hélène Haegel, Anneliese Schneider et al. · Journal for ImmunoTherapy of Cancer · 2021 · 43 citations · Full text

Medicine, Oncology, Pharmacology +17

JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy

Gabrielle Leclercq-Cohen, Hélène Haegel, Alberto Toso et al. · Journal for ImmunoTherapy of Cancer · 2022 · 35 citations · Full text

Medicine, Immunology, Pharmacology +17